Literature DB >> 33257283

Association of apolipoprotein C3 with insulin resistance and coronary artery calcium in patients with type 1 diabetes.

Teresa Buckner1, Baohai Shao2, Robert H Eckel3, Jay W Heinecke2, Karin E Bornfeldt4, Janet Snell-Bergeon5.   

Abstract

BACKGROUND: Apolipoprotein C3 (APOC3) is a risk factor for incident coronary artery disease in people with type 1 diabetes (T1D). The pathways that link elevated APOC3 levels to an increased risk of incident cardiovascular disease in people with T1D are not understood.
OBJECTIVE: To explore potential mechanisms, we investigated the association of APOC3 with insulin resistance and coronary artery calcium (CAC).
METHODS: In a random subcohort of participants with T1D from Coronary Artery Calcification in Type 1 Diabetes (n = 134), serum APOC3, high-density lipoprotein (HDL)-associated APOC3, and retinol binding protein 4 (RBP4; a potential marker of insulin resistance) were measured by targeted mass spectrometry. We used linear regression to evaluate associations of serum APOC3 and HDL-APOC3 with APOB, non-HDL cholesterol, serum- and HDL-associated RBP4, and estimated insulin sensitivity and logistic regression to evaluate association with presence of CAC, adjusted for age, sex, and diabetes duration.
RESULTS: Serum APOC3 correlated positively with APOB and non-HDL cholesterol and was associated with increased odds of CAC (odds ratio: 1.68, P = .024). Estimated insulin sensitivity was not associated with serum- or HDL-RBP4 but was negatively associated with serum APOC3 in men (ß estimate: -0.318, P = .0040) and decreased odds of CAC (odds ratio: 0.434, P = .0023).
CONCLUSIONS: Serum APOC3 associates with increased insulin resistance and CAC in T1D.
Copyright © 2020 National Lipid Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Apolipoproteins; Diabetes; Epidemiology; HDL; Insulin resistance

Mesh:

Substances:

Year:  2020        PMID: 33257283      PMCID: PMC7887020          DOI: 10.1016/j.jacl.2020.10.006

Source DB:  PubMed          Journal:  J Clin Lipidol        ISSN: 1876-4789            Impact factor:   5.365


  52 in total

1.  Antisense-Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes.

Authors:  Andres Digenio; Richard L Dunbar; Veronica J Alexander; Marcus Hompesch; Linda Morrow; Richard G Lee; Mark J Graham; Steven G Hughes; Rosie Yu; Walter Singleton; Brenda F Baker; Sanjay Bhanot; Rosanne M Crooke
Journal:  Diabetes Care       Date:  2016-06-06       Impact factor: 19.112

2.  Effects of APOC3 Heterozygous Deficiency on Plasma Lipid and Lipoprotein Metabolism.

Authors:  Gissette Reyes-Soffer; Carol Sztalryd; Richard B Horenstein; Stephen Holleran; Anastasiya Matveyenko; Tiffany Thomas; Renu Nandakumar; Colleen Ngai; Wahida Karmally; Henry N Ginsberg; Rajasekhar Ramakrishnan; Toni I Pollin
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-01       Impact factor: 8.311

3.  High-Density Lipoprotein Subspecies Defined by Presence of Apolipoprotein C-III and Incident Coronary Heart Disease in Four Cohorts.

Authors:  Majken K Jensen; Sarah A Aroner; Kenneth J Mukamal; Jeremy D Furtado; Wendy S Post; Michael Y Tsai; Anne Tjønneland; Joseph F Polak; Eric B Rimm; Kim Overvad; Robyn L McClelland; Frank M Sacks
Journal:  Circulation       Date:  2017-11-21       Impact factor: 29.690

4.  Insulin resistance is a prominent feature of insulin-dependent diabetes.

Authors:  R A DeFronzo; R Hendler; D Simonson
Journal:  Diabetes       Date:  1982-09       Impact factor: 9.461

5.  Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia.

Authors:  Daniel Gaudet; Veronica J Alexander; Brenda F Baker; Diane Brisson; Karine Tremblay; Walter Singleton; Richard S Geary; Steven G Hughes; Nicholas J Viney; Mark J Graham; Rosanne M Crooke; Joseph L Witztum; John D Brunzell; John J P Kastelein
Journal:  N Engl J Med       Date:  2015-07-30       Impact factor: 91.245

6.  Effect of type 1 diabetes on the gender difference in coronary artery calcification: a role for insulin resistance? The Coronary Artery Calcification in Type 1 Diabetes (CACTI) Study.

Authors:  Dana Dabelea; Gregory Kinney; Janet K Snell-Bergeon; John E Hokanson; Robert H Eckel; James Ehrlich; Satish Garg; Richard F Hamman; Marian Rewers
Journal:  Diabetes       Date:  2003-11       Impact factor: 9.461

7.  Insulin resistance in adolescents with type 1 diabetes and its relationship to cardiovascular function.

Authors:  Kristen J Nadeau; Judith G Regensteiner; Timothy A Bauer; Mark S Brown; Jennifer L Dorosz; Amber Hull; Phil Zeitler; Boris Draznin; Jane E B Reusch
Journal:  J Clin Endocrinol Metab       Date:  2009-11-13       Impact factor: 5.958

Review 8.  Volanesorsen for treatment of patients with familial chylomicronemia syndrome.

Authors:  B A Warden; P B Duell
Journal:  Drugs Today (Barc)       Date:  2018-12       Impact factor: 2.245

9.  Apolipoprotein C-III inhibits triglyceride hydrolysis by GPIHBP1-bound LPL.

Authors:  Mikael Larsson; Christopher M Allan; Rachel S Jung; Patrick J Heizer; Anne P Beigneux; Stephen G Young; Loren G Fong
Journal:  J Lipid Res       Date:  2017-07-10       Impact factor: 5.922

10.  Plasma Levels of Retinol Binding Protein 4 Relate to Large VLDL and Small LDL Particles in Subjects with and without Type 2 Diabetes.

Authors:  Hanna Wessel; Ali Saeed; Janette Heegsma; Margery A Connelly; Klaas Nico Faber; Robin P F Dullaart
Journal:  J Clin Med       Date:  2019-10-25       Impact factor: 4.241

View more
  5 in total

1.  CREBH normalizes dyslipidemia and halts atherosclerosis in diabetes by decreasing circulating remnant lipoproteins.

Authors:  Masami Shimizu-Albergine; Debapriya Basu; Jenny E Kanter; Farah Kramer; Vishal Kothari; Shelley Barnhart; Carissa Thornock; Adam E Mullick; Noemie Clouet-Foraison; Tomas Vaisar; Jay W Heinecke; Robert A Hegele; Ira J Goldberg; Karin E Bornfeldt
Journal:  J Clin Invest       Date:  2021-11-15       Impact factor: 14.808

Review 2.  The Remnant Lipoprotein Hypothesis of Diabetes-Associated Cardiovascular Disease.

Authors:  Karin E Bornfeldt
Journal:  Arterioscler Thromb Vasc Biol       Date:  2022-05-26       Impact factor: 10.514

3.  Apolipoprotein C-III predicts cardiovascular events and mortality in individuals with type 1 diabetes and albuminuria.

Authors:  Fanny Jansson Sigfrids; Lars Stechemesser; Emma H Dahlström; Carol M Forsblom; Valma Harjutsalo; Raimund Weitgasser; Marja-Riitta Taskinen; Per-Henrik Groop
Journal:  J Intern Med       Date:  2021-11-24       Impact factor: 13.068

Review 4.  Genes and Longevity of Lifespan.

Authors:  May Nasser Bin-Jumah; Muhammad Shahid Nadeem; Sadaf Jamal Gilani; Fahad A Al-Abbasi; Inam Ullah; Sami I Alzarea; Mohammed M Ghoneim; Sultan Alshehri; Aziz Uddin; Bibi Nazia Murtaza; Imran Kazmi
Journal:  Int J Mol Sci       Date:  2022-01-28       Impact factor: 5.923

Review 5.  Cardiovascular disease in diabetes, beyond glucose.

Authors:  Robert H Eckel; Karin E Bornfeldt; Ira J Goldberg
Journal:  Cell Metab       Date:  2021-07-21       Impact factor: 31.373

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.